Please assess the completion status of the following clinical trial:

Trial Title: Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Chronic migraine headache - Diagnostic criteria:~A. Headache (tension-type-like and/or migraine-like) on 15 days per month for \>3 months2 and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura~C. On 8 days per month for \>3 months, fulfilling any of the following 3 :~1. criteria C and D for 1.1 Migraine without aura~2. criteria B and C for 1.2 Migraine with aura~3. believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative D. Not better accounted for by another ICHD-3 diagnosis. -~Exclusion Criteria:~Previous exposure at any time to any botulinum toxin serotype Pregnancy, breastfeeding or plans to become pregnant within 6 months Age \<18 years Failure to complete at least 20 days of headache diary in the 28 day baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A 100U (Type: EXPERIMENTAL): None
- Group A 155U (Type: EXPERIMENTAL): None
- Group B 100U (Type: EXPERIMENTAL): None
- Group B 155 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).